Total Debt Reduction of $244 Million in 2024, Capping a Two-Year Total Debt Reduction of $647 Million
2025 Guidance Midpoint Indicates Double-Digit Adjusted EBITDA & Adjusted EPS Growth, and Improving Cash Flow
Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services (P&HS) Segment
Board of Directors Authorizes Share Repurchase Program of Up to $100 Million
RICHMOND, Va.–(BUSINESS WIRE)–Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the fourth quarter and year ended December 31, 2024.
“We are pleased with the progress that we have made against the strategy as outlined at our Investor Day in December 2023. As a reminder, we committed to optimizing our Products & Healthcare Services business, leveraging our leading Patient Direct platform, and building balance sheet flexibility through deleveraging. Within P&HS we continue to see momentum in broadening our product portfolio, developing a streamlined and efficient manufacturing footprint, and enhancing our distribution capabilities. Within Patient Direct, we continue to leverage our footprint and broad product offering to support home-based care for millions of patients with chronic conditions. These capabilities, combined with positive demographic trends and expanding home treatment options, leaves us very bullish on the future of this business. Finally, we repaid $647 million of debt over the last two years which helps provide the financial flexibility to pursue the acquisition of Rotech – which we believe will drive long-term shareholder value,” said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor.
Pesicka added, “Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy. As a logical next step, we have been actively engaged in robust discussions regarding the potential sale of our Products & Healthcare Services segment.”
Pesicka concluded, “In the meantime, we remain focused on delivering a strong 2025 and are confident in our ability to achieve double-digit adjusted EBITDA growth while improving cash flow.”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Financial Summary (1) (2) |
|
|
|
|
|
|
|
FYE |
|
FYE |
|||||
|
($ in millions, except per share data) |
|
4Q24 |
|
4Q23 |
|
2024 |
|
2023 |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Revenue |
|
$ |
2,696 |
|
|
$ |
2,656 |
|
$ |
10,701 |
|
|
$ |
10,334 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Operating (loss) income, GAAP |
|
$ |
(262 |
) |
|
$ |
60 |
|
$ |
(208 |
) |
|
$ |
105 |
|
|
Adj. Operating Income, Non-GAAP |
|
$ |
95 |
|
|
$ |
111 |
|
$ |
313 |
|
|
$ |
305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Net (loss) income, GAAP |
|
$ |
(296 |
) |
|
$ |
18 |
|
$ |
(363 |
) |
|
$ |
(41 |
) |
|
Adj. Net Income, Non-GAAP |
|
$ |
43 |
|
|
$ |
54 |
|
$ |
119 |
|
|
$ |
106 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Adj. EBITDA, Non-GAAP |
|
$ |
138 |
|
|
$ |
170 |
|
$ |
523 |
|
|
$ |
526 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Net (loss) income per common share, GAAP |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
|
Adj. Net Income per share, Non-GAAP |
|
$ |
0.55 |
|
|
$ |
0.69 |
|
$ |
1.53 |
|
|
$ |
1.36 |
|
|
(1) Reconciliations of the differences between the non-GAAP financial measures presented in this release and their most directly comparable GAAP financial measures are included in the tables below. |
|||||||||||||||
|
(2) Non-GAAP results in this table exclude a goodwill impairment charge of $305 million, net of tax. Refer to footnote (3) of the GAAP/Non-GAAP Reconciliations below. |
|||||||||||||||
Share Repurchase Authorization
On February 26, 2025, the Owens & Minor Board of Directors authorized a share repurchase program of up to $100 million over the next 24 months. Under the program, Owens & Minor may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions and 10b5-1 trading plans.
2025 Financial Outlook
The Company issued its outlook for 2025; summarized below:
- Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion
- Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million
- Adjusted EPS for 2025 to be in a range of $1.60 to $1.85
The Company’s outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
Key assumptions supporting the Company’s 2025 financial guidance include:
- Gross margin of 20.75% to 21.25%
- Interest expense of $138 million to $142 million
- Adjusted effective tax rate of 29.0% to 30.0%
- Diluted weighted average shares of ~80 million
- Capital expenditures, gross, of $250 million to $270 million
- Stable commodity prices
- FX rates as of 12/31/2024
Although the Company does provide guidance for adjusted EBITDA and adjusted EPS (which are non-GAAP financial measures), it is not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP without unreasonable effort. Certain elements of the composition of the GAAP amounts are not predictable, making it impracticable for the Company to forecast. Such elements include, but are not limited to, exit and realignment charges and acquisition-related charges, which could have a significant and unpredictable impact on our GAAP results. As a result, no GAAP guidance or reconciliation of the Company’s adjusted EBITDA guidance or adjusted EPS guidance is provided. The outlook is based on certain assumptions that are subject to the risk factors discussed in the Company’s filings with the SEC.
Financial Advisor
Citi is serving as exclusive financial advisor to Owens & Minor in connection with the potential sale of the Products & Healthcare Services (P&HS) segment.
Investor Conference Call for Fourth Quarter and Full Year 2024 Financial Results
Owens & Minor will host a conference call for investors and analysts on Friday, February 28, 2025, at 8:30 a.m. EST. Participants may access the call via the toll-free dial-in number at 1-888-300-2035, or the toll dial-in number at 1-646-517-7437. The conference ID access code is 1058917. All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/. A replay of the webcast can be accessed following the presentation at the link provided above.
Safe Harbor
This release is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the public in compliance with the SEC’s Fair Disclosure Regulation. This release contains certain “forward-looking” statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements in this release regarding our future prospects and performance, including our expectations with respect to our financial performance, our 2025 financial results, Owens & Minor’s ability to successfully complete the sale of the P&HS business in any specific transaction on favorable terms or at all, our ability to raise additional financing for our acquisition of Rotech on favorable terms or at all, the risk that the proposed acquisition of Rotech will not be consummated in a timely manner or at all, our cost-saving initiatives, future indebtedness and growth, industry trends, as well as statements related to our expectations regarding the performance of our business, including our ability to address macro and market conditions. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated in the forward-looking statements. Investors should refer to Owens & Minor’s Annual Report on Form 10-K for the year ended December 31, 2024, expected to be filed with the SEC on or around February 28, 2025, including the section captioned “Item 1A. Risk Factors,” as applicable, and subsequent quarterly reports on Form 10-Q and current reports on Form 8-K filed with or furnished to the SEC, for a discussion of certain known risk factors that could cause the Company’s actual results to differ materially from its current estimates. These filings are available at www.owens-minor.com. Given these risks and uncertainties, Owens & Minor can give no assurance that any forward-looking statements will, in fact, transpire and, therefore, cautions investors not to place undue reliance on them. Owens & Minor specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
* Registered Trademark or Trademark of O&M Halyard or its affiliates.
|
Exhibit 99.1 |
|||||||
|
Owens & Minor, Inc. |
|||||||
|
Consolidated Statements of Operations (unaudited) |
|||||||
|
(dollars in thousands, except per share data) |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
|||||
|
|
|
2024 |
|
2023 |
|||
|
Net revenue |
|
$ |
2,696,073 |
|
|
$ |
2,656,150 |
|
Cost of goods sold |
|
|
2,116,307 |
|
|
|
2,086,227 |
|
Gross profit |
|
|
579,766 |
|
|
|
569,923 |
|
Distribution, selling and administrative expenses |
|
|
493,066 |
|
|
|
457,225 |
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
Acquisition-related charges and intangible amortization |
|
|
25,148 |
|
|
|
26,427 |
|
Exit and realignment charges, net |
|
|
24,632 |
|
|
|
24,310 |
|
Other operating (income) expense, net |
|
|
(8,225 |
) |
|
|
1,940 |
|
Operating (loss) income |
|
|
(261,967 |
) |
|
|
60,021 |
|
Interest expense, net |
|
|
35,696 |
|
|
|
36,863 |
|
Loss on extinguishment of debt |
|
|
790 |
|
|
|
860 |
|
Other expense, net |
|
|
1,199 |
|
|
|
1,301 |
|
(Loss) income before income taxes |
|
|
(299,652 |
) |
|
|
20,997 |
|
Income tax (benefit) provision |
|
|
(3,535 |
) |
|
|
3,213 |
|
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
|
|
|
|
|
|
|
|
|
Net (loss) income per common share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
Diluted |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
Owens & Minor, Inc. |
||||||||
|
Consolidated Statements of Operations (unaudited) |
||||||||
|
(dollars in thousands, except per share data) |
||||||||
|
|
|
|
|
|
|
|
||
|
|
|
Years Ended December 31, |
||||||
|
|
|
2024 |
|
2023 |
||||
|
Net revenue |
|
$ |
10,700,883 |
|
|
$ |
10,333,967 |
|
|
Cost of goods sold |
|
|
8,481,728 |
|
|
|
8,208,806 |
|
|
Gross profit |
|
|
2,219,155 |
|
|
|
2,125,161 |
|
|
Distribution, selling and administrative expenses |
|
|
1,909,791 |
|
|
|
1,813,559 |
|
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
|
Acquisition-related charges and intangible amortization |
|
|
86,543 |
|
|
|
101,037 |
|
|
Exit and realignment charges, net |
|
|
110,162 |
|
|
|
99,127 |
|
|
Other operating expense, net |
|
|
13,316 |
|
|
|
6,930 |
|
|
Operating (loss) income |
|
|
(207,769 |
) |
|
|
104,508 |
|
|
Interest expense, net |
|
|
143,804 |
|
|
|
157,915 |
|
|
Loss (gain) on extinguishment of debt |
|
|
1,101 |
|
|
|
(3,518 |
) |
|
Other expense, net |
|
|
4,683 |
|
|
|
4,837 |
|
|
Loss before income taxes |
|
|
(357,357 |
) |
|
|
(54,726 |
) |
|
Income tax provision (benefit) |
|
|
5,329 |
|
|
|
(13,425 |
) |
|
Net loss |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
|
|
|
|
|
|
|
|
||
|
Net loss per common share: |
|
|
|
|
|
|
||
|
Basic |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
|
Diluted |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
|
|
Owens & Minor, Inc. |
||||||
|
Condensed Consolidated Balance Sheets (unaudited) |
||||||
|
(dollars in thousands) |
||||||
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
December 31, |
||
|
|
|
2024 |
|
2023 |
||
|
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
49,382 |
|
$ |
243,037 |
|
Accounts receivable, net |
|
|
690,241 |
|
|
598,257 |
|
Merchandise inventories |
|
|
1,131,879 |
|
|
1,110,606 |
|
Other current assets |
|
|
149,515 |
|
|
150,890 |
|
Total current assets |
|
|
2,021,017 |
|
|
2,102,790 |
|
Property and equipment, net |
|
|
509,347 |
|
|
543,972 |
|
Operating lease assets |
|
|
355,627 |
|
|
296,533 |
|
Goodwill |
|
|
1,331,281 |
|
|
1,638,846 |
|
Intangible assets, net |
|
|
298,726 |
|
|
361,835 |
|
Other assets, net |
|
|
140,158 |
|
|
149,346 |
|
Total assets |
|
$ |
4,656,156 |
|
$ |
5,093,322 |
|
Liabilities and equity |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Accounts payable |
|
$ |
1,251,964 |
|
$ |
1,171,882 |
|
Accrued payroll and related liabilities |
|
|
151,039 |
|
|
116,398 |
|
Current portion of long-term debt |
|
|
45,549 |
|
|
206,904 |
|
Other current liabilities |
|
|
425,187 |
|
|
396,701 |
|
Total current liabilities |
|
|
1,873,739 |
|
|
1,891,885 |
|
Long-term debt, excluding current portion |
|
|
1,808,047 |
|
|
1,890,598 |
|
Operating lease liabilities, excluding current portion |
|
|
286,212 |
|
|
222,429 |
|
Deferred income taxes, net |
|
|
22,456 |
|
|
41,652 |
|
Other liabilities |
|
|
100,476 |
|
|
122,592 |
|
Total liabilities |
|
|
4,090,930 |
|
|
4,169,156 |
|
Total equity |
|
|
565,226 |
|
|
924,166 |
|
Total liabilities and equity |
|
$ |
4,656,156 |
|
$ |
5,093,322 |
|
Owens & Minor, Inc. |
||||||||
|
Consolidated Statements of Cash Flows (unaudited) |
||||||||
|
(dollars in thousands) |
||||||||
|
|
|
|
|
|
|
|
||
|
|
|
Three Months Ended December 31, |
||||||
|
|
|
2024 |
|
2023 |
||||
|
Operating activities: |
|
|
|
|
|
|
||
|
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
|
Adjustments to reconcile net (loss) income to cash provided by operating activities: |
|
|
|
|
|
|
||
|
Depreciation and amortization |
|
|
65,187 |
|
|
|
70,737 |
|
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
|
Share-based compensation expense |
|
|
7,555 |
|
|
|
5,801 |
|
|
Loss on extinguishment of debt |
|
|
790 |
|
|
|
860 |
|
|
Deferred income tax benefit |
|
|
(10,996 |
) |
|
|
(7,333 |
) |
|
Changes in operating lease right-of-use assets and lease liabilities |
|
|
3,088 |
|
|
|
1,470 |
|
|
Gain from sales and dispositions of property and equipment |
|
|
(7,023 |
) |
|
|
(8,420 |
) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
|
Accounts receivable |
|
|
(33,663 |
) |
|
|
88,457 |
|
|
Merchandise inventories |
|
|
106,205 |
|
|
|
(22,719 |
) |
|
Accounts payable |
|
|
(99,074 |
) |
|
|
(15,341 |
) |
|
Net change in other assets and liabilities |
|
|
25,434 |
|
|
|
(22,497 |
) |
|
Other, net |
|
|
2,503 |
|
|
|
2,966 |
|
|
Cash provided by operating activities |
|
|
71,001 |
|
|
|
111,765 |
|
|
Investing activities: |
|
|
|
|
|
|
||
|
Additions to property and equipment |
|
|
(62,834 |
) |
|
|
(50,392 |
) |
|
Additions to computer software |
|
|
(8,602 |
) |
|
|
(5,933 |
) |
|
Proceeds from sales of property and equipment |
|
|
18,667 |
|
|
|
17,929 |
|
|
Other, net |
|
|
465 |
|
|
|
(518 |
) |
|
Cash used for investing activities |
|
|
(52,304 |
) |
|
|
(38,914 |
) |
|
Financing activities: |
|
|
|
|
|
|
||
|
Borrowings under amended Receivables Financing Agreement |
|
|
179,400 |
|
|
|
— |
|
|
Repayments under amended Receivables Financing Agreement |
|
|
(179,400 |
) |
|
|
— |
|
|
Borrowings under Revolving Credit Facility |
|
|
635,800 |
|
|
|
— |
|
|
Repayments under Revolving Credit Facility |
|
|
(635,800 |
) |
|
|
— |
|
|
Repayments of debt |
|
|
(32,750 |
) |
|
|
(50,504 |
) |
|
Other, net |
|
|
(10,346 |
) |
|
|
(711 |
) |
|
Cash used for financing activities |
|
|
(43,096 |
) |
|
|
(51,215 |
) |
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(1,309 |
) |
|
|
1,128 |
|
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
(25,708 |
) |
|
|
22,764 |
|
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
75,090 |
|
|
|
250,160 |
|
|
Cash, cash equivalents and restricted cash at end of period(1) |
|
$ |
49,382 |
|
|
$ |
272,924 |
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
|
Income taxes (received) paid, net |
|
$ |
(2,057 |
) |
|
$ |
515 |
|
|
Interest paid |
|
$ |
37,269 |
|
|
$ |
52,168 |
|
|
Noncash investing activity: |
|
|
|
|
|
|
||
|
Unpaid purchases of property and equipment and computer software at end of period |
|
$ |
84,562 |
|
|
$ |
77,279 |
|
| _________________ | ||||||||
|
(1) There was no restricted cash as of December 31, 2024. Restricted cash as of September 30, 2024 was $30 million and includes amounts held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives related to wind-down costs of a subsidiary, Fusion5, as well as restricted cash deposits received under the Master Receivables Purchase Agreement to be remitted to a third-party financial institution. |
||||||||
|
Owens & Minor, Inc. |
||||||||
|
Consolidated Statements of Cash Flows (unaudited) |
||||||||
|
(dollars in thousands) |
||||||||
|
|
|
|
|
|
|
|
||
|
|
|
Years Ended December 31, |
||||||
|
|
|
2024 |
|
2023 |
||||
|
Operating activities: |
|
|
|
|
|
|
||
|
Net loss |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
|
Adjustments to reconcile net loss to cash provided by operating activities: |
|
|
|
|
|
|
||
|
Depreciation and amortization |
|
|
264,775 |
|
|
|
287,377 |
|
|
Goodwill impairment charge |
|
|
307,112 |
|
|
|
— |
|
|
Share-based compensation expense |
|
|
26,836 |
|
|
|
23,218 |
|
|
Loss (gain) on extinguishment of debt |
|
|
1,101 |
|
|
|
(3,518 |
) |
|
Deferred income tax benefit |
|
|
(26,115 |
) |
|
|
(23,648 |
) |
|
Changes in operating lease right-of-use assets and lease liabilities |
|
|
10,244 |
|
|
|
(47 |
) |
|
Gain from sales and dispositions of property and equipment |
|
|
(44,705 |
) |
|
|
(34,882 |
) |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
|
Accounts receivable |
|
|
(94,550 |
) |
|
|
165,167 |
|
|
Merchandise inventories |
|
|
(26,228 |
) |
|
|
224,338 |
|
|
Accounts payable |
|
|
65,187 |
|
|
|
30,997 |
|
|
Net change in other assets and liabilities |
|
|
30,153 |
|
|
|
100,370 |
|
|
Other, net |
|
|
10,371 |
|
|
|
12,639 |
|
|
Cash provided by operating activities |
|
|
161,495 |
|
|
|
740,710 |
|
|
Investing activities: |
|
|
|
|
|
|
||
|
Additions to property and equipment |
|
|
(210,865 |
) |
|
|
(190,870 |
) |
|
Additions to computer software |
|
|
(17,297 |
) |
|
|
(17,022 |
) |
|
Proceeds from sales of property and equipment |
|
|
103,426 |
|
|
|
71,574 |
|
|
Other, net |
|
|
8,203 |
|
|
|
(936 |
) |
|
Cash used for investing activities |
|
|
(116,533 |
) |
|
|
(137,254 |
) |
|
Financing activities: |
|
|
|
|
|
|
||
|
Borrowings under amended Receivables Financing Agreement |
|
|
1,465,800 |
|
|
|
476,000 |
|
|
Repayments under amended Receivables Financing Agreement |
|
|
(1,465,800 |
) |
|
|
(572,000 |
) |
|
Borrowings under Revolving Credit Facility |
|
|
635,800 |
|
|
|
— |
|
|
Repayments under Revolving Credit Facility |
|
|
(635,800 |
) |
|
|
— |
|
|
Repayments of debt |
|
|
(244,197 |
) |
|
|
(320,693 |
) |
|
Other, net |
|
|
(23,406 |
) |
|
|
(637 |
) |
|
Cash used for financing activities |
|
|
(267,603 |
) |
|
|
(417,330 |
) |
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
|
|
(901 |
) |
|
|
613 |
|
|
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
|
(223,542 |
) |
|
|
186,739 |
|
|
Cash, cash equivalents and restricted cash at beginning of period |
|
|
272,924 |
|
|
|
86,185 |
|
|
Cash, cash equivalents and restricted cash at end of period(1) |
|
$ |
49,382 |
|
|
$ |
272,924 |
|
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
|
Income taxes paid (received), net |
|
$ |
5,553 |
|
|
$ |
(6,283 |
) |
|
Interest paid |
|
$ |
141,547 |
|
|
$ |
153,247 |
|
|
Noncash investing activity: |
|
|
|
|
|
|
||
|
Unpaid purchases of property and equipment and computer software at end of period |
|
$ |
84,562 |
|
|
$ |
77,279 |
|
| _________________ | ||||||||
|
(1) There was no restricted cash as of December 31, 2024. Restricted cash as of December 31, 2023 was $30 million and includes amounts held in an escrow account as required by the Centers for Medicare & Medicaid Services (CMS) in conjunction with the Bundled Payments for Care Improvement (BPCI) initiatives related to wind-down costs of a subsidiary, Fusion5, as well as restricted cash deposits received under the Master Receivables Purchase Agreement to be remitted to a third-party financial institution. |
||||||||
|
Owens & Minor, Inc. |
||||||||||||||
|
Summary Segment Information (unaudited) |
||||||||||||||
|
(dollars in thousands) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Three Months Ended December 31, |
|
|||||||||||
|
|
|
2024 |
|
|
2023 |
|
||||||||
|
|
|
|
|
|
% of |
|
|
|
|
|
% of |
|
||
|
|
|
|
|
|
consolidated |
|
|
|
|
|
consolidated |
|
||
|
|
|
Amount |
|
net revenue |
|
|
Amount |
|
net revenue |
|
||||
|
Net revenue: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
2,001,050 |
|
|
74.22 |
% |
$ |
1,991,716 |
|
|
74.99 |
% |
|
|
Patient Direct |
|
|
695,023 |
|
|
25.78 |
% |
|
664,434 |
|
|
25.01 |
% |
|
|
Consolidated net revenue |
|
$ |
2,696,073 |
|
|
100.00 |
% |
$ |
2,656,150 |
|
|
100.00 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
% of segment |
|
|
|
|
% of segment |
|
|||
|
Operating income: |
|
|
|
|
net revenue |
|
|
|
|
net revenue |
|
|||
|
Products & Healthcare Services |
|
$ |
25,825 |
|
|
1.29 |
% |
$ |
33,244 |
|
|
1.67 |
% |
|
|
Patient Direct |
|
|
69,558 |
|
|
10.01 |
% |
|
77,514 |
|
|
11.67 |
% |
|
|
Acquisition-related charges and intangible amortization |
|
|
(25,148 |
) |
|
|
|
|
(26,427 |
) |
|
|
|
|
|
Exit and realignment charges, net |
|
|
(24,632 |
) |
|
|
|
|
(24,310 |
) |
|
|
|
|
|
Goodwill impairment charge |
|
|
(307,112 |
) |
|
|
|
|
— |
|
|
|
|
|
|
Litigation and related charges (1) |
|
|
(458 |
) |
|
|
|
|
— |
|
|
|
|
|
|
Consolidated operating (loss) income |
|
$ |
(261,967 |
) |
|
|
|
$ |
60,021 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
11,407 |
|
|
|
|
$ |
12,019 |
|
|
|
|
|
|
Patient Direct |
|
|
34,959 |
|
|
|
|
|
36,685 |
|
|
|
|
|
|
Intangible amortization |
|
|
13,770 |
|
|
|
|
|
20,831 |
|
|
|
|
|
|
Other (2) |
|
|
5,051 |
|
|
|
|
|
1,202 |
|
|
|
|
|
|
Consolidated depreciation and amortization |
|
$ |
65,187 |
|
|
|
|
$ |
70,737 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
20,920 |
|
|
|
|
$ |
11,405 |
|
|
|
|
|
|
Patient Direct |
|
|
50,516 |
|
|
|
|
|
44,920 |
|
|
|
|
|
|
Consolidated capital expenditures |
|
$ |
71,436 |
|
|
|
|
$ |
56,325 |
|
|
|
|
|
|
(1) |
Litigation and related charges are reported within Other operating (income) expense, net in our Statements of Operations. Refer to footnote 4 in the GAAP/Non-GAAP Reconciliations below. |
|
|
(2) |
Other depreciation and amortization expense is captured within exit and realignment charges, net or acquisition-related charges and intangible amortization for the three months ended December 31, 2024 and 2023. |
|
Owens & Minor, Inc. |
||||||||||||||
|
Summary Segment Information (unaudited) |
||||||||||||||
|
(dollars in thousands) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
Years Ended December 31, |
|
|||||||||||
|
|
|
2024 |
|
|
2023 |
|
||||||||
|
|
|
|
|
|
% of |
|
|
|
|
% of |
|
|||
|
|
|
|
|
|
consolidated |
|
|
|
|
consolidated |
|
|||
|
|
|
Amount |
|
net revenue |
|
Amount |
|
net revenue |
|
|||||
|
Net revenue: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
8,020,771 |
|
|
74.95 |
% |
$ |
7,781,395 |
|
|
75.30 |
% |
|
|
Patient Direct |
|
|
2,680,112 |
|
|
25.05 |
% |
|
2,552,572 |
|
|
24.70 |
% |
|
|
Consolidated net revenue |
|
$ |
10,700,883 |
|
|
100.00 |
% |
$ |
10,333,967 |
|
|
100.00 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
% of segment |
|
|
|
|
% of segment |
|
|||
|
Operating income: |
|
|
|
|
net revenue |
|
|
|
|
net revenue |
|
|||
|
Products & Healthcare Services |
|
$ |
53,012 |
|
|
0.66 |
% |
$ |
57,809 |
|
|
0.74 |
% |
|
|
Patient Direct |
|
|
260,155 |
|
|
9.71 |
% |
|
246,863 |
|
|
9.67 |
% |
|
|
Acquisition-related charges and intangible amortization |
|
|
(86,543 |
) |
|
|
|
|
(101,037 |
) |
|
|
|
|
|
Exit and realignment charges, net |
|
|
(110,162 |
) |
|
|
|
|
(99,127 |
) |
|
|
|
|
|
Goodwill impairment charge |
|
|
(307,112 |
) |
|
|
|
|
— |
|
|
|
|
|
|
Litigation and related charges (1) |
|
|
(17,119 |
) |
|
|
|
|
— |
|
|
|
|
|
|
Consolidated operating (loss) income |
|
$ |
(207,769 |
) |
|
|
|
$ |
104,508 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
45,835 |
|
|
|
|
$ |
47,756 |
|
|
|
|
|
|
Patient Direct |
|
|
141,032 |
|
|
|
|
|
152,583 |
|
|
|
|
|
|
Intangible amortization |
|
|
64,943 |
|
|
|
|
|
83,522 |
|
|
|
|
|
|
Other (2) |
|
|
12,965 |
|
|
|
|
|
3,516 |
|
|
|
|
|
|
Consolidated depreciation and amortization |
|
$ |
264,775 |
|
|
|
|
$ |
287,377 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Capital expenditures: |
|
|
|
|
|
|
|
|
|
|
|
|||
|
Products & Healthcare Services |
|
$ |
50,050 |
|
|
|
|
$ |
29,361 |
|
|
|
|
|
|
Patient Direct |
|
|
178,112 |
|
|
|
|
|
178,531 |
|
|
|
|
|
|
Consolidated capital expenditures |
|
$ |
228,162 |
|
|
|
|
$ |
207,892 |
|
|
|
|
|
|
(1) |
Litigation and related charges are reported within Other operating (income) expense, net in our Statements of Operations. Refer to footnote 4 in the GAAP/Non-GAAP Reconciliations below. |
|
|
(2) |
Other depreciation and amortization expense is captured within exit and realignment charges, net or acquisition-related charges and intangible amortization for the years ended December 31, 2024 and 2023. |
|
Owens & Minor, Inc. |
|||||||||||||||
|
Net (Loss) Income Per Common Share (unaudited) |
|||||||||||||||
|
(dollars in thousands, except per share data) |
|||||||||||||||
|
|
|
Three Months Ended December 31, |
|
Years Ended December 31, |
|||||||||||
|
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|||||||
|
Net (loss) income |
|
$ |
(296,117 |
) |
|
$ |
17,784 |
|
$ |
(362,686 |
) |
|
$ |
(41,301 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Weighted average shares outstanding – basic |
|
|
77,169 |
|
|
|
76,284 |
|
|
76,741 |
|
|
|
75,785 |
|
|
Dilutive shares |
|
|
— |
|
|
|
1,491 |
|
|
— |
|
|
|
— |
|
|
Weighted average shares outstanding – diluted |
|
|
77,169 |
|
|
|
77,775 |
|
|
76,741 |
|
|
|
75,785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Net (loss) income per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Basic |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
|
Diluted |
|
$ |
(3.84 |
) |
|
$ |
0.23 |
|
$ |
(4.73 |
) |
|
$ |
(0.54 |
) |
|
Share-based awards of approximately 1.4 million and 1.5 million shares for the three months and year ended December 31, 2024 and 1.6 million for the year ended December 31, 2023 were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. |
|||||||||||||||
Contacts
Investors
Alpha IR Group
Jackie Marcus or Nick Teves
[email protected]
Jonathan Leon
Executive Vice President & Chief Financial Officer
[email protected]
Media
Stacy Law
[email protected]
